Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals focuses on developing and delivering novel medicines for individuals living with rare and serious liver diseases.

Intercept Pharmaceuticals

Intercept Pharmaceuticals | 64,582 followers on LinkedIn. Our mission is to build a healthier tomorrow for patients with rare and serious liver diseases. | We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). 

In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs.

Janet Lewis

Chief Information Officer, at Intercept Pharmaceuticals Inc.

William Wallace

Rare Disease Therapeutic Business Specialist at Intercept Pharmaceuticals | 20+ years in the Pharmaceutical Industry | Territory Turnaround…

Grady Mateen

Director, Field Medical, Medical Science Liaison at Intercept Pharmaceuticals

Arash Thranian, PhD., MBA

Over several years, Cecilia was bounced from doctor to doctor until she found someone who finally listened to her concerns and properly diagnosed her with primary biliary cholangitis ( #PBC ). Ensuring patient voices are heard and understood is a critical aspect of healthcare, and especially important when diagnosing and managing #rarediseases . Watch Cecilia recount her experience with PBC.

We had a great time at #ACG2024 discussing the latest scientific research with the #liver community.

As we wrap up #LiverAwarenessMonth , we want to thank all those who contribute to raising awareness for #liverdisease - in October and beyond!

We’re excited to be at #ACG2024 ! Come visit us at booth #831 or at our product theater at 6:15 pm today, October 27.

Receiving a diagnosis in a rare disease like primary biliary cholangitis ( #PBC ) can take a long time, but early detection may lead to better disease management. Listen as Cecilia describes her own hunt for answers. #LiverAwarenessMonth

We were proud to support and attend the Liver Coalition of San Diego 's Liver Excellence Gala! Thank you for all that you do for the #liverdisease community. #LiverAwarenessMonth

Cecilia’s experience with primary biliary cholangitis ( #PBC ) taught her the importance of advocating for herself. Listen as she encourages others to ensure their voices are heard. #LiverAwarenessMonth

In honor of #HispanicHeritageMonth , we spoke with our very own Rosa Rodriguez about why celebrating this month is important: "Empowered Hispanic women in biotech are not just shaping the future of science - they are also forging paths for future generations, proving that innovation knows no boundaries and that diversity drives progress."

Another great year supporting the American Liver Foundation 's National Legacy Gala and gathering with those who have made an impact on the #liverdisease community! #LiverAwarenessMonth

Welcome to Intercept, Dr. Veruska Di Sena ! We're excited to have you join our team as Senior Vice President of Medical Affairs.

Metric
Company Name	Intercept Pharmaceuticals, Inc.
Symbol	ICPT
MSH ID	COM:INTERCEPTPHARMA
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	341
Website	interceptpharma.com
LinkedIn	intercept-pharmaceuticals
Founders

Metric
Market Cap	794.69M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	285.71M
Revenue (LTM)
Revenue (NTM)
Gross Profit	284.73M
EBITDA	-61.70M
Operating Income	-68.22M
Net Income	115.17M
EPS	3.40
Diluted EPS	3.40
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1.00
Operating Profit Margin	-0.20
EBITDA Margin	-0.22
Net Profit Margin	-0.18
Return on Equity	-0.78
Return on Assets	-0.15
Return on Capital Employed	-0.21

COM:INTERCEPTPHARMA

Intercept Pharmaceuticals

Last Close

18.96

07/11 21:00

Market Cap

794.69M

Beta: -

Volume Today

3.91M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-13.55
P/B Ratio	11.05
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.50
EV Multiple	-16.16

Metric
Days Sales Outstanding	37.32
Days Payables Outstanding	5.92K
Days Inventory Outstanding	1.53K
Operating Cycle	1.56K
Cash Conversion Cycle	-4.36K
Asset Turnover	0.81

Metric
Operating Cash Flow	-26.78M
Free Cash Flow	-27.35M
Cash Flow to Debt	-0.28
Operating Cash Flow/Sales	-0.20
Free Cash Flow Yield	-0.08

Metric
Cash & Equivalents	50.52M
Accounts Receivable	1.48M
Inventory	6.46M
Goodwill
Debt to Capitalization	0.76
Debt to Assets	0.57
Current Ratio	4.22
Quick Ratio	3.91

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.08
R&D to Revenue	0.51
SG&A to Revenue